Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 54

1.

Erratum to: Analysis of necroptotic proteins in failing human hearts.

Szobi A, Gonçalvesová E, Varga ZV, Leszek P, Kuśmierczyk M, Hulman M, Kyselovič J, Ferdinandy P, Adameová A.

J Transl Med. 2017 May 11;15(1):103. doi: 10.1186/s12967-017-1207-7. No abstract available.

2.

Analysis of necroptotic proteins in failing human hearts.

Szobi A, Gonçalvesová E, Varga ZV, Leszek P, Kuśmierczyk M, Hulman M, Kyselovič J, Ferdinandy P, Adameová A.

J Transl Med. 2017 Apr 28;15(1):86. doi: 10.1186/s12967-017-1189-5. Erratum in: J Transl Med. 2017 May 11;15(1):103.

3.

Disordered myocardial Ca(2+) homeostasis results in substructural alterations that may promote occurrence of malignant arrhythmias.

Tribulova N, Knezl V, Szeiffova Bacova B, Egan Benova T, Viczenczova C, Gonçalvesova E, Slezak J.

Physiol Res. 2016 Sep 19;65 Suppl 1:S139-48.

4.

European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions.

Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, Ferrari R, Piepoli MF, Delgado Jimenez JF, Metra M, Fonseca C, Hradec J, Amir O, Logeart D, Dahlström U, Merkely B, Drozdz J, Goncalvesova E, Hassanein M, Chioncel O, Lainscak M, Seferovic PM, Tousoulis D, Kavoliuniene A, Fruhwald F, Fazlibegovic E, Temizhan A, Gatzov P, Erglis A, Laroche C, Mebazaa A; Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

Eur J Heart Fail. 2016 Jun;18(6):613-25. doi: 10.1002/ejhf.566. Erratum in: Eur J Heart Fail. 2017 Mar;19(3):438.

5.

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members.

Eur Heart J. 2016 Jul 14;37(27):2129-200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20. No abstract available. Erratum in: Eur Heart J. 2016 Dec 30;:.

PMID:
27206819
6.

Necroptotic cell death in failing heart: relevance and proposed mechanisms.

Adameova A, Goncalvesova E, Szobi A, Dhalla NS.

Heart Fail Rev. 2016 Mar;21(2):213-21. doi: 10.1007/s10741-016-9537-8. Review.

PMID:
26872672
7.

Selexipag for the Treatment of Pulmonary Arterial Hypertension.

Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV; GRIPHON Investigators.

N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184.

8.

Ten-year survival and prognostic markers in one thousand patients with advanced heart failure. A single-centre analysis.

Lesny P, Luknar M, Matejka M, Varga I, Solik P, Wimmerova S, Goncalvesova E.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Jun;160(2):257-62. doi: 10.5507/bp.2015.049. Epub 2015 Oct 23.

9.

Functional and circulatory renal changes in advanced heart failure.

Demesova E, Goncalvesova E, Slezak P, Pontuch P.

Bratisl Lek Listy. 2015;116(2):83-7.

PMID:
25665471
10.

Clinical implementation of cardiac resynchronization therapy-regional disparities across selected ESC member countries.

Hatala R, Lunati M, Calvi V, Favale S, Goncalvesová E, Haim M, Jovanovic V, Kaczmarek K, Kautzner J, Merkely B, Pokushalov E, Revishvili A, Theodorakis G, Vatasescu R, Zalevsky V, Zupan I, Vicini I, Corbucci G.

Ann Noninvasive Electrocardiol. 2015 Jan;20(1):43-52. doi: 10.1111/anec.12243. Epub 2014 Dec 26.

11.

Intracoronary mesenchymal stem cell transplantation in patients with ischemic cardiomyopathy.

Lakota J, Dubrovcakova M, Bohovic R, Goncalvesova E.

Int J Cardiol. 2014 Sep 20;176(2):547-9. doi: 10.1016/j.ijcard.2014.07.024. Epub 2014 Jul 11. No abstract available.

PMID:
25049010
12.

[Liver in heart failure].

Goncalvesová E.

Vnitr Lek. 2014 Apr;60(4):298-303. Review. Czech.

PMID:
24985988
13.

Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial.

Maggioni AP, Greene SJ, Fonarow GC, Böhm M, Zannad F, Solomon SD, Lewis EF, Baschiera F, Hua TA, Gimpelewicz CR, Lesogor A, Gheorghiade M; ASTRONAUT Investigators and Coordinators.

Eur Heart J. 2013 Oct;34(40):3117-27. doi: 10.1093/eurheartj/eht342. Epub 2013 Sep 2.

14.

Macitentan and morbidity and mortality in pulmonary arterial hypertension.

Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G; SERAPHIN Investigators.

N Engl J Med. 2013 Aug 29;369(9):809-18. doi: 10.1056/NEJMoa1213917.

15.

Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry.

Maggioni AP, Anker SD, Dahlström U, Filippatos G, Ponikowski P, Zannad F, Amir O, Chioncel O, Leiro MC, Drozdz J, Erglis A, Fazlibegovic E, Fonseca C, Fruhwald F, Gatzov P, Goncalvesova E, Hassanein M, Hradec J, Kavoliuniene A, Lainscak M, Logeart D, Merkely B, Metra M, Persson H, Seferovic P, Temizhan A, Tousoulis D, Tavazzi L; Heart Failure Association of the ESC.

Eur J Heart Fail. 2013 Oct;15(10):1173-84. doi: 10.1093/eurjhf/hft134. Epub 2013 Aug 26.

16.

Dietary omega-3 fatty acids attenuate myocardial arrhythmogenic factors and propensity of the heart to lethal arrhythmias in a rodent model of human essential hypertension.

Radosinska J, Bacova B, Knezl V, Benova T, Zurmanova J, Soukup T, Arnostova P, Slezak J, Gonçalvesova E, Tribulova N.

J Hypertens. 2013 Sep;31(9):1876-85. doi: 10.1097/HJH.0b013e328362215d.

PMID:
23719203
17.

The long-term response to treatment with calcium channel blockers in a patient with idiopathic pulmonary arterial hypertension.

Solik P, Lesny P, Luknar M, Varga I, Goncalvesova E.

Bratisl Lek Listy. 2013;114(5):283-6.

PMID:
23611052
18.

Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.

Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP; ASTRONAUT Investigators and Coordinators.

JAMA. 2013 Mar 20;309(11):1125-35. doi: 10.1001/jama.2013.1954. Erratum in: JAMA. 2013 Apr 10;309(14):1461.

PMID:
23478743
19.

The effects of phosphodiesterase 5 inhibition on hemodynamics, functional status and survival in advanced heart failure and pulmonary hypertension: a case-control study.

Reichenbach A, Al-Hiti H, Malek I, Pirk J, Goncalvesova E, Kautzner J, Melenovsky V.

Int J Cardiol. 2013 Sep 20;168(1):60-5. doi: 10.1016/j.ijcard.2012.09.074. Epub 2012 Oct 8.

PMID:
23058346
20.

Up-regulation of myocardial connexin-43 in spontaneously hypertensive rats fed red palm oil is most likely implicated in its anti-arrhythmic effects.

Bačová B, Radošinská J, Viczenczová C, Knezl V, Dosenko V, Beňova T, Navarová J, Gonçalvesová E, van Rooyen J, Weismann P, Slezák J, Tribulová N.

Can J Physiol Pharmacol. 2012 Sep;90(9):1235-45. doi: 10.1139/y2012-103. Epub 2012 Aug 22.

PMID:
22908996

Supplemental Content

Loading ...
Support Center